–  Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund

– 本轮投资由新投资者Kurma Partners和Angelini Ventures共同领投，现有投资者EDBI、ClavystBio和Boehringer Ingelheim Venture Fund也积极参与。

– Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-related dilated cardiomyopathy (LMNA DCM) through to clinical proof-of-concept

– 所得款项将用于支持主要候选药物NVC-001在LMNA相关扩张型心肌病（LMNA DCM）患者中的1/2期临床试验，直至临床概念验证。

SINGAPORE

新加坡

and

和

PHILADELPHIA

费城

,

，

May 6, 2025

2025年5月6日

/PRNewswire/ --

/PRNewswire/ --

Nuevocor

新科鲁（Nuevocor）

, a

，一个

Singapore

新加坡

-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the successful completion of

总部位于IND阶段的生物技术公司，专注于开发由异常机械生物学驱动的心肌病治疗方法，近日宣布成功完成

US$45 million

4500万美元

Series B financing. The round was co-led by Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio and Boehringer Ingelheim Venture Fund, alongside Highlight Capital and SEEDS Capital. Nuevocor is pleased to welcome Amanda Gett-Chaperot, PhD (Kurma Partners) and .

B轮融资。本轮融资由库玛合伙人公司和安吉里尼风险投资公司共同领投，现有投资者EDBI、ClavystBio和勃林格殷格翰风险基金，以及高亮资本和SEEDS资本也积极参与。Nuevocor很高兴欢迎阿曼达·盖特-查佩罗特博士（库玛合伙人公司）加入。

Elia Stupka

埃利亚·斯图普卡

, PhD (Angelini Ventures) to its Board of Directors.

，博士（Angelini Ventures）加入其董事会。

The new investment will support a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM, with clinical trial sites across the U.S. and

新的投资将支持在美国各地的临床试验中心进行NVC-001在LMNA DCM患者中的首次人体、开放标签、多中心、递增单剂量的1/2期临床试验。

Europe

欧洲

. Additionally, the company will establish an office in

此外，公司还将在以下地点设立办事处：

Paris, France

法国巴黎

, to support clinical development and bring

，以支持临床开发并带来

Singapore

新加坡

innovation to patients globally.

全球患者带来的创新。

LMNA DCM is a genetic heart condition caused by mutations in the LMNA gene, leading to the weakening and enlargement of the heart muscle, ultimately resulting in a rapid progression toward end-stage heart failure. LMNA DCM is estimated to affect more than 100,000 patients in the U.S. and

LMNA DCM 是一种由 LMNA 基因突变引起的遗传性心脏病，会导致心肌的削弱和扩大，最终快速进展为终末期心力衰竭。据估计，LMNA DCM 在美国影响超过 100,000 名患者，并且

Europe

欧洲

. NVC-001 and other pipeline assets are derived from Nuevocor's proprietary PrOSIA

NVC-001和其他管线资产源自Nuevocor的专有PrOSIA技术。

TM

商标

mechanobiology platform, which pinpoints the functional root-cause of many cardiomyopathies.

机械生物学平台，可以精确定位许多心肌病的功能性根本原因。

'We are delighted to secure this significant financing milestone to build a global company with such an experienced syndicate of international life science investors,' said

“我们很高兴能够获得这一重要的融资里程碑，与这样一群经验丰富的国际生命科学投资者共同建立一家全球性公司，”

Dr.

博士

Yann Chong Tan

颜忠谭

, PhD, CEO and Co-Founder of Nuevocor

博士，Nuevocor首席执行官兼联合创始人

. 'The continued strong support from insiders and the addition of new investors will enable Nuevocor to continue its strong momentum and advance NVC-001 into the clinic. This is an example of how

“内部人士的持续大力支持以及新投资者的加入将使Nuevocor能够继续保持强劲的发展势头，并推动NVC-001进入临床阶段。这是一个如何

Singapore

新加坡

is bringing transformative innovation to the rest of the world.'

正在为世界其他地区带来变革性的创新。'

'Nuevocor is providing new hope to a significant population of cardiovascular patients who today lack treatment options by directly targeting the underlying causes of disease,' said

“Nuevocor 通过直接针对疾病的潜在原因，为目前缺乏治疗选择的大量心血管病患者提供了新的希望，”

Dr. Amanda Gett-Chaperot, Partner at Kurma Partners

阿曼达·盖特-查佩罗特博士，库尔玛合伙人的合伙人

. 'The burden of cardiomyopathies is large, and Kurma is excited to join Nuevocor, investing from our new Biofund IV to create meaningful value through the treatment of these important diseases.'

“心肌病的负担很大，Kurma 很高兴加入 Nuevocor，通过我们的新 Biofund IV 进行投资，为治疗这些重要疾病创造有意义的价值。”

'Our investment in Nuevocor marks a strategic expansion for Angelini Ventures – into cardiovascular disease, gene therapy, and the

“我们对Nuevocor的投资标志着Angelini Ventures的战略扩展——进入心血管疾病、基因治疗以及

Singapore

新加坡

biotech ecosystem. We are excited by Nuevocor's novel approach to treating genetic-dilated cardiomyopathy by targeting mechanobiological pathways rather than simply replacing genes. This one-time therapy has the potential to transform patient outcomes and ease healthcare burdens. We are proud to support their mission and join the Board, alongside Kurma, ClavystBio, EDBI, Boehringer Ingelheim Venture Fund, and other investors, as the company grows globally, including into .

生物技术生态系统。Nuevocor通过靶向机械生物学通路而非简单替换基因来治疗遗传性扩张型心肌病的创新方法让我们感到兴奋。这种一次性治疗有潜力改变患者的治疗结果并减轻医疗负担。我们很自豪能够支持他们的使命，并与Kurma、ClavystBio、EDBI、勃林格殷格翰风险基金以及其他投资者一起加入董事会，伴随该公司在全球范围内，包括进入 的成长过程。

Europe

欧洲

,' said

`，' 说

Dr.

博士

Elia Stupka

埃利亚·斯图普卡

, Managing Director at Angelini Ventures

，Angelini Ventures董事总经理

.

。

About NVC-001

关于NVC-001

NVC-001 is a first-in-class, AAV-based gene therapy candidate for the treatment of LMNA-related dilated cardiomyopathy (LMNA DCM), one of the most aggressive forms of  DCM with a rapid progression toward end-stage heart failure and malignant ventricular arrhythmias associated with increased risk of sudden cardiac death.

NVC-001是一种基于AAV的、首创新药基因疗法候选药物，用于治疗与LMNA相关的扩张型心肌病（LMNA DCM），这是DCM中最具有侵袭性的形式之一，其快速进展为终末期心力衰竭，并伴有恶性室性心律失常，导致猝死风险增加。

LMNA DCM is estimated to affect more than 100,000 patients in the U.S. and .

据估计，美国有超过10万名患者受到LMNA DCM的影响。

Europe

欧洲

. NVC-001 is designed to reduce forces to the nucleus to restore nuclear envelope integrity, a hallmark of LMNA DCM, and treat disease. NVC-001 has demonstrated dramatic survival benefits in preclinical models, high transduction levels and a clean safety profile in both GLP toxicology studies and large animal models.

NVC-001旨在减少对细胞核的作用力，以恢复核膜完整性，这是LMNA DCM的标志性特征，并用于治疗疾病。NVC-001在临床前模型中显示出显著的生存益处，在GLP毒理学研究和大型动物模型中表现出高转导水平和良好的安全性。

Nuevocor plans to initiate a Phase 1/2 clinical trial in early 2026, with sites in the U.S. and .

Nuevocor计划在2026年初启动一期/二期临床试验，地点设在美国和。

Europe

欧洲

, and a concurrent natural history study.

，并发自然史研究。

About Nuevocor

关于Nuevocor

Nuevocor is an IND-stage biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in

Nuevocor是一家处于IND阶段的生物技术公司，致力于开发针对由异常机械生物学驱动的遗传性心肌病的新疗法，总部位于

Singapore

新加坡

with an office in the U.S. and expanding to

在美国设有办事处并扩展到

Europe

欧洲

. Our unique approach, enabled by our proprietary PrOSIA

. 我们独特的方法，得益于我们专有的PrOSIA技术

TM

商标

mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options.

机械生物学平台超越了传统基因替代疗法的局限性——该疗法仅针对个别基因突变进行治疗——通过针对疾病的根源，治疗多种心肌病中共有的疾病通路缺陷。Nuevocor 首次针对那些无法通过基因替代疗法解决且没有有效治疗方案的遗传性心肌病。

(.

(.

www.nuevocor.com

www.nuevocor.com

)

)

About Kurma Partners

关于库尔马合伙人

Founded in 2009 in

成立于2009年

Paris

巴黎

, Kurma Partners has become a key player in

，Kurma Partners 已成为关键参与者在

Europe

欧洲

, financing innovation to build the healthcare industry of tomorrow. Kurma invests from company formation to growth capital, across the spectrum of healthcare through specialized franchises. The franchises continue to expand with successive funds focused on biotechnology (Biofunds I, II, III, IV), digital health & diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and more recently, growth opportunities (Kurma Growth Opportunity Fund).

，为打造未来的医疗保健行业提供创新融资。Kurma从公司成立到成长资本，在整个医疗保健领域通过专业特许经营进行投资。这些特许经营随着专注于生物技术（Biofunds I、II、III、IV）、数字健康与诊断（Kurma Diagnostics 和 Kurma Diagnostics 2）以及最近的成长机会（Kurma Growth Opportunity Fund）的连续基金而不断扩大。

Kurma's teams based in .

库尔马的团队基于 。

Paris

巴黎

and

和

Munich

慕尼黑

are embedded within the European ecosystem and have strong international networks spanning prestigious research institutes and hospitals, entrepreneurs, industry and investors. Kurma Partners is part of the Eurazeo group. (

嵌入欧洲生态系统，并拥有强大的国际网络，覆盖知名研究机构和医院、企业家、行业和投资者。Kurma Partners 是 Eurazeo 集团的一部分。

www.kurmapartners.com

www.kurmapartners.com

)

)

About Angelini Ventures

关于 Angelini Ventures

Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in biotech and digital health. Angelini Ventures will invest €300 million across a global portfolio, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies.

Angelini Ventures是Angelini Industries的风险投资部门，是一家专注于加速生物技术和数字健康领域颠覆性创新和趋势的A轮和B轮投资公司。Angelini Ventures将通过全球团队、战略顾问和合作伙伴，在全球范围内投资3亿欧元，帮助企业家将其企业发展为变革性的行业领军企业。

To date, Angelini Ventures has invested around €100 million into 18 companies covering a range of therapeutic areas and modalities. Its biotech portfolio includes Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The digital health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis.

迄今为止，Angelini Ventures已向涵盖多种治疗领域和模式的18家公司投资了约1亿欧元。其生物技术组合包括Neumirna、Cour Pharmaceuticals、Nouscom、Pretzel Therapeutics和Freya Biosciences。数字健康组合包括Vantis Health、Avation、Cadence Neuroscience、Nobi、Noctrix和Serenis。

(.

(。

www.angeliniventures.com

www.angeliniventures.com

)

)

About EDBI

关于EDBI

EDBI operates under SG Growth Capital, the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore. We invest in high-growth global technology companies and industry leaders looking to scale in

EDBI隶属于新加坡经济发展局（EDB）和新加坡企业发展局的投资平台SG Growth Capital。我们投资于高增长的全球技术公司和希望扩展业务的行业领导者。

Singapore

新加坡

and across

并且横跨

Asia

亚洲

. Leveraging SG Growth Capital's extensive networks and expertise, we collaborate with our portfolio companies to unlock growth opportunities, create pathways for advancement, and connect them with the resources needed for success. Through strategic investments and partnerships, we drive the development of innovative solutions, create good jobs, and contribute to .

利用SG增长资本的广泛网络和专业知识，我们与我们的投资组合公司合作，挖掘增长机会，创建发展途径，并将它们与成功所需的资源联系起来。通过战略投资和合作伙伴关系，我们推动创新解决方案的发展，创造良好的就业机会，并作出贡献。

Singapore's

新加坡的

long-term economic resilience. (

长期经济韧性。

www.edbi.com/)

www.edbi.com/)

About ClavystBio

关于ClavystBio

ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies from

ClavystBio 是一家由淡马锡创立的生命科学领域投资机构和创业孵化器，致力于将突破性创意快速转化为健康影响力。我们与创新者、企业家和创始人合作，投资并支持他们创立和发展全球性公司。

Singapore

新加坡

. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community.

我们的关注范围涵盖治疗学、数字健康和医疗技术，重点是首创新的科学和技术。我们的协作空间Node 1为那些已经从孵化器毕业的企业提供即插即用的空间，以帮助它们迈向下一个里程碑。通过将初创企业聚集在一起，我们营造了一个充满活力且互相支持的社区。

Since our inception in 2022, ClavystBio has committed over US .

自2022年成立以来，ClavystBio已投入超过美元。

$220 million

2.2亿美元

in investments in the life sciences sector. (

在生命科学领域的投资方面。

www.clavystbio.com

www.clavystbio.com

)

)

About Boehringer Ingelheim Venture Fund

关于勃林格殷格翰风险基金

The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is dedicated to investing in groundbreaking biotechnology companies that are at the forefront of therapeutic and digital innovations, aiming to advance biomedical research. With a commitment to revolutionizing the standard of care, the BIVF fosters long-term partnerships with scientists and entrepreneurs.

勃林格殷格翰风险基金（BIVF）成立于2010年，致力于投资处于治疗和数字创新前沿的突破性生物技术公司，旨在推动生物医学研究的发展。通过致力于革新医疗标准，BIVF与科学家和企业家建立了长期合作伙伴关系。

The BIVF's focus is on nurturing disease-modifying therapeutic concepts and facilitating their clinical application. The BIVF prioritizes the translation of first-in-class concepts that address significant medical needs in fields such as oncology, immunology, regenerative medicine, neurodegeneration, infectious diseases, and digital health technologies.

BIVF 的重点在于培育疾病修饰治疗概念并促进其临床应用。BIVF 优先转化首创概念，以应对在肿瘤学、免疫学、再生医学、神经退行性疾病、传染病和数字健康技术等领域中的重大医疗需求。

These innovative concepts often encompass novel platform technologies designed to tackle targets and diseases that were previously considered untreatable. With a fund volume of .

这些创新概念通常涵盖旨在解决以前被认为无法治疗的靶点和疾病的新平台技术。基金规模为。

EUR 350 million

3.5亿欧元

, the BIVF operates as an evergreen fund, continually reinvesting to fuel its mission. The partners of the BIVF gain from the fund's deep expertise in drug discovery & development, translational science, and management, along with access to a network of experts within the Boehringer Ingelheim organization.

，BIVF作为常青基金运作，不断再投资以推动其使命。BIVF的合作伙伴从基金在药物发现与开发、转化科学及管理方面的深厚专业知识中获益，同时还能接触到来自勃林格殷格翰组织内部的专家网络。

Currently, the BIVF supports a diverse portfolio of over 40 companies, leveraging its extensive experience to drive progress in healthcare. (.

目前，BIVF 支持着一个由 40 多家公司组成的多元化投资组合，利用其丰富的经验推动医疗保健领域的进步。

www.boehringer-ingelheim-venture.com

www.boehringer-ingelheim-venture.com

)

)

SOURCE Nuevocor

来源 新科罗

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用